NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Lupin Launches Sugammadex Injection in the U.S. Following FDA Approval
Lupin has received U.S. FDA approval and announced the immediate launch of Sugammadex Injection (200 mg/2 mL and 500 mg/5 mL) in the United States. The product is a bioequivalent version of Merck's Bridion®, used for reversing neuromuscular blockade in surgical patients aged 2 and older. This launch strengthens Lupin's complex generic and injectable portfolio, which is a key driver for its U.S. business where it currently ranks as the 3rd largest player by prescriptions. Given Lupin's TTM revenue of ₹27,958 Cr, high-value injectable launches are critical for maintaining its 31.5% operating profit margin.
உச்சம் நம்பிக்கை
என்ன மாறியதுLupin has received final regulatory clearance and commenced the commercial sale of Sugammadex Injection in the U.S. market.
ஏன் இது முக்கியம்This launch adds a high-value injectable to Lupin's U.S. portfolio, supporting its strategy to move away from commoditized generics toward complex formulations with higher entry barriers and better margins.
Product Strengths: 200 mg/2 mL and 500 mg/5 mLTTM வருவாய்: ₹27,958 கோடிU.S. Market Rank: 3rd largest by prescriptionsOperating Profit Margin (TTM): 31.5%
📅 குறுகிய காலம்The immediate launch is expected to provide a marginal boost to U.S. generic sales and sentiment in the coming weeks.
📈 நீண்ட காலம்Consistent launches in the complex generic space are vital for Lupin to sustain its 24% expected growth rate and improve ROCE, which currently stands at 27%.
⚠ அபாய எச்சரிக்கைகள்
Generic price erosion in the U.S. market
Competition from other generic manufacturers for the same molecule
Consolidation of U.S. payers
👀 கவனிக்க வேண்டியவை
Investors should monitor the U.S. revenue growth in the upcoming quarters to gauge the market share capture of this molecule. Additionally, watch for any further approvals in the complex injectable pipeline which are intended to offset generic price erosion.
82.2% Stake in Kaveri Therapeutics via $1.6M Oncology Program Spin-out
Lupin's US subsidiary has spun out two oncology programs, LNP7457 (PRMT5) and LNP8701 (SOS1), into a newly formed clinical-stage entity, Kaveri Therapeutics. In exchange for granting exclusive perpetual licenses valued at USD 1.6 million, Lupin has acquired an 82.2% equity stake (332,000 shares) in Kaveri. This strategic move allows Lupin to advance these therapies for solid tumors through a specialized vehicle that will raise independent capital for global clinical trials. While the immediate financial impact is small relative to Lupin's Rs 27,958 Cr TTM revenue, it optimizes R&D spending while retaining significant ownership.
உச்சம் நம்பிக்கை
என்ன மாறியதுLupin has transitioned two early-stage oncology assets into a majority-owned independent subsidiary to facilitate specialized development and external funding.
ஏன் இது முக்கியம்This allows Lupin to offload the high costs of global clinical trials to a separate entity while maintaining a majority stake in the potential upside of high-value oncology therapies.
Equity Stake Acquired: 82.2%Consideration Value: USD 1.6 millionShares Acquired: 332,000 Common SharesDeal Value vs TTM Revenue: ~0.05%Target Net Worth: NIL
📅 குறுகிய காலம்Neutral; the transaction is small in financial terms and will not impact immediate earnings, though it reflects a proactive R&D strategy.
📈 நீண்ட காலம்Strategic; if the oncology programs succeed in clinical trials, Kaveri could become a high-value asset or a candidate for a future IPO/exit, benefiting Lupin's valuation.
⚠ அபாய எச்சரிக்கைகள்
Clinical trial failure risk for early-stage oncology programs
Execution risk for a newly incorporated entity
Potential dilution of Lupin's stake as Kaveri raises external capital
👀 கவனிக்க வேண்டியவை
Monitor Kaveri's ability to raise external capital and the clinical trial progression of the PRMT5 and SOS1 programs, as these are the primary drivers of value for this new subsidiary.
₹18 Dividend Declared; Lupin Schedules 44th AGM for August 4, 2026
Lupin Limited has issued a notice for its 44th Annual General Meeting (AGM) scheduled for August 4, 2026, where it will seek shareholder approval for a final dividend of ₹18 per equity share (900% of face value). The company's Integrated Report for FY 2025-26 highlights significant R&D progress, including the filing of Ranibizumab in the U.S. and Denosumab in Japan. Additionally, Lupin has entered a strategic collaboration with TB Alliance for the commercialization of Telacebec across 140 countries. The board has also proposed the appointment of Deloitte Haskins & Sells as statutory auditors for a five-year term.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized the dividend payout and provided a comprehensive update on its transition toward complex generics and biosimilars through its FY26 Integrated Report.
ஏன் இது முக்கியம்The ₹18 dividend represents a steady payout relative to the TTM EPS of ₹116.74. The progress in biosimilars and NCEs is critical for maintaining the 31.5% OPM and offsetting generic price erosion in the U.S. market.
Final Dividend: ₹18 per shareDividend as % of Face Value: 900%Cost Auditor Remuneration (FY27): ₹10,00,000AGM Date: ஆகஸ்ட் 04, 2026Cut-off date for e-voting: ஜூலை 28, 2026
📅 குறுகிய காலம்The stock may see neutral to positive movement as investors react to the dividend confirmation and the detailed R&D pipeline updates provided in the integrated report.
📈 நீண்ட காலம்Structural growth is tied to the successful commercialization of the biosimilar pipeline and expansion into European markets (Italy/Spain), which are expected to drive margin expansion over the next 2-3 years.
⚠ அபாய எச்சரிக்கைகள்
US generic price erosion
USFDA warning letters at Tarapur and Mandideep facilities
Consolidation of payers in the US generics market
👀 கவனிக்க வேண்டியவை
Investors should note the record date/cut-off date of July 28, 2026, for dividend eligibility and e-voting. Key focus should remain on the execution timeline for the U.S. Ranibizumab launch and the integration of the Nanomi B.V. acquisition expected by December 2025.
₹18 Dividend: Lupin Sets July 17, 2026, as Record Date for 900% Final Payout
Lupin Limited has finalized July 17, 2026, as the record date for its final dividend of ₹18 per equity share (900% of face value). This dividend was previously recommended by the Board on May 07, 2026, and is now subject to shareholder approval at the upcoming 44th AGM on August 04, 2026. Based on the TTM EPS of ₹116.74, the payout ratio stands at approximately 15.4%. The company maintains a strong financial position with a low debt-to-equity ratio of 0.04 and TTM PAT of ₹5,356 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has officially scheduled its 44th AGM and fixed the record date for the ₹18 per share final dividend recommended earlier in May.
ஏன் இது முக்கியம்The dividend confirms the company's commitment to shareholder returns, supported by a strong ROCE of 27% and significant margin expansion seen in recent quarters (OPM at 31.5%).
Dividend per share: ₹18Dividend % of Face Value: 900%ரெக்கார்ட் தேதி: ஜூலை 17, 2026Estimated Payout vs TTM PAT: ~15.4%TTM EPS: ₹116.74
📅 குறுகிய காலம்The stock price is expected to adjust downwards by the dividend amount on the ex-dividend date (typically one business day prior to the record date).
📈 நீண்ட காலம்Limited; this is a routine annual dividend distribution consistent with the company's profitability profile.
👀 கவனிக்க வேண்டியவை
Investors seeking the dividend must hold the shares in their demat account by the record date of July 17, 2026. Watch for management commentary during the August 4 AGM regarding the Nanomi B.V. acquisition and USFDA facility status.
Lupin Receives US FDA EIR with VAI Classification for Somerset Facility
Lupin has received the Establishment Inspection Report (EIR) from the U.S. FDA for its manufacturing facility in Somerset, New Jersey. The inspection, conducted from April 13 to April 17, 2026, resulted in a Voluntary Action Indicated (VAI) classification. This is a positive regulatory outcome, indicating that the facility meets acceptable compliance standards, which is crucial for Lupin as the 3rd largest pharmaceutical player in the U.S. by prescriptions. With TTM revenue of ₹27,958 Cr, maintaining compliant U.S. facilities is essential for sustaining its core export business.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe U.S. FDA has concluded its review of the Somerset facility inspection, granting it a VAI status, which effectively clears the site for continued operations and new approvals.
ஏன் இது முக்கியம்Regulatory compliance in the U.S. is critical for Lupin's margins, especially since niche categories like inhalations contribute 42% of U.S. revenue. A VAI status avoids the restrictive 'Official Action Indicated' (OAI) status that can halt new product launches.
Inspection Start Date: ஏப்ரல் 13, 2026Inspection End Date: ஏப்ரல் 17, 2026TTM வருவாய்: ₹27,958 கோடிசந்தை மதிப்பு: ₹1,09,919 கோடிU.S. Market Rank: 3rd largest by prescriptions
📅 குறுகிய காலம்The announcement removes regulatory uncertainty regarding the Somerset facility, likely providing a neutral-to-positive sentiment boost in the coming weeks.
📈 நீண்ட காலம்Ensures the Somerset facility remains a viable part of Lupin's global supply chain, supporting its long-term strategy in complex generics and biosimilars.
⚠ அபாய எச்சரிக்கைகள்
US generic price erosion
Regulatory risks at other facilities (Tarapur and Mandideep)
Payer consolidation in the US market
👀 கவனிக்க வேண்டியவை
Investors should monitor for any new product approvals (ANDAs) linked to the Somerset facility, as the VAI status clears the path for future U.S. launches from this site.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Lupin Increases Stake in Philippines Subsidiary MPPI to 99.89% via Nanomi B.V.
Lupin Limited has successfully consolidated its ownership in Multicare Pharmaceuticals Philippines, Inc. (MPPI), increasing its stake from 56.28% to 99.89%. This was achieved through the acquisition of 11,794,497 shares by Lupin's wholly-owned Dutch subsidiary, Nanomi B.V., alongside a buyback of 61,118 shares by MPPI. The transaction, effective July 01, 2026, simplifies the corporate structure and gives Lupin near-total control over its Philippines operations. A minor buyback of 30,559 shares remains in progress to complete the transition.
உச்சம் நம்பிக்கை
என்ன மாறியதுLupin transitioned from a majority owner to a near-100% owner of its Philippines-based subsidiary, MPPI, through its Dutch arm Nanomi B.V.
ஏன் இது முக்கியம்This move eliminates minority interest leakage, allowing nearly 100% of MPPI's profits to accrue to Lupin's shareholders and providing full operational control in a key emerging market.
Stake Increase: 56.28% முதல் 99.89% வரைShares Acquired: 11,794,497Shares Bought Back: 61,118Pending Buyback: 30,559TTM வருவாய்: Rs 27,958 கோடி
📅 குறுகிய காலம்The news confirms the execution of previously announced plans and is likely to be viewed neutrally to slightly positively by the market as it streamlines the corporate structure.
📈 நீண்ட காலம்Strategically positive as it strengthens Lupin's footprint in Southeast Asia and simplifies global governance, though the financial impact depends on the standalone scale of the Philippines business.
⚠ அபாய எச்சரிக்கைகள்
Acquisition cost for the minority stake was not disclosed in this filing
👀 கவனிக்க வேண்டியவை
Investors should monitor upcoming quarterly results for the full consolidation of MPPI's earnings and management commentary regarding growth targets in the Philippines market.
EMA Approves Lupin's NaMuscla Expansion for Pediatric Use with New Strengths
Lupin has received European Medicines Agency (EMA) approval to expand the indication of NaMuscla to include pediatric patients (ages 6-17) for the treatment of non-dystrophic myotonic disorders (NDM). The approval introduces two new dosage strengths, 62 mg and 83 mg, supplementing the existing 167 mg capsule. NaMuscla remains the only approved treatment for NDM symptoms in Europe, a rare condition with a prevalence of 1 in 100,000. This regulatory milestone supports Lupin's specialty portfolio growth in Europe, following its recent €190 million (approx. ₹2,000 Cr) expansion into Italy and Spain.
உச்சம் நம்பிக்கை
என்ன மாறியதுLupin's NaMuscla, previously approved only for adults in Europe, now has marketing authorization for pediatric and adolescent patients with new lower-dose strengths.
ஏன் இது முக்கியம்This strengthens Lupin's specialty drug pipeline in Europe, a key growth pillar intended to offset US generic price erosion. While the patient population is small (rare disease), specialty products typically command better pricing and margins than commoditized generics.
New Dosage Strengths: 62 mg and 83 mgDisease Prevalence: 1:100,000Recent EU Expansion Investment: €190 millionTTM வருவாய்: ₹27,958 கோடிOperating Profit Margin: 31.5%
📅 குறுகிய காலம்The news is sentimentally positive for the stock as it demonstrates progress in the high-margin specialty segment, though immediate revenue impact will be gradual due to reimbursement timelines.
📈 நீண்ட காலம்Supports Lupin's structural shift toward complex generics and specialty medicines, which is critical for maintaining its 27% ROCE and 31.5% OPM in the face of global pricing pressures.
⚠ அபாய எச்சரிக்கைகள்
Limited addressable market due to rare disease status
National reimbursement hurdles in individual EU countries
Execution risk in European market expansion
👀 கவனிக்க வேண்டியவை
Watch for the timeline of national reimbursement and access processes across European markets, which will determine the actual revenue ramp-up for these new indications.
Lupin Receives Tentative U.S. FDA Approval for Enzalutamide Tablets (40mg to 160mg)
Lupin has received tentative approval from the U.S. FDA for its Abbreviated New Drug Application for Enzalutamide Tablets in 40 mg, 80 mg, 120 mg, and 160 mg strengths. The 40 mg and 80 mg versions are bioequivalent to the reference drug Xtandi by Astellas, which is used in oncology. Lupin is also introducing 120 mg and 160 mg strengths to provide alternative dosing options for healthcare providers. This approval strengthens Lupin's specialty pipeline in the U.S. market, although a commercial launch will depend on final approval and patent timelines.
முக்கிய அம்சங்கள்
Received tentative U.S. FDA approval for Enzalutamide Tablets in four strengths: 40 mg, 80 mg, 120 mg, and 160 mg.The 40 mg and 80 mg strengths are bioequivalent to the reference listed drug (RLD) Xtandi Tablets of Astellas.Lupin is offering unique 120 mg and 160 mg strengths to provide alternative dosing options for patients.The product targets the oncology segment, expanding Lupin's complex generic portfolio in the United States.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development for Lupin's U.S. pipeline, though they should monitor the timeline for final approval and patent expiry of the innovator drug for actual revenue impact.
Lupin Launches Azilsartan Medoxomil in US with 180-Day First-to-File Exclusivity
Lupin Limited has launched Azilsartan Medoxomil Tablets (40mg and 80mg) in the United States following US FDA approval. The company holds exclusive first-to-file status for this product, making it eligible for 180 days of generic drug exclusivity. The tablets are a generic version of Edarbi®, used for treating hypertension, and address a market valued at approximately USD 53.5 million in annual sales as of April 2026.
முக்கிய அம்சங்கள்
Launched Azilsartan Medoxomil Tablets in 40mg and 80mg strengths in the U.S. market.Granted exclusive first-to-file status with 180-day generic drug exclusivity.Targets the U.S. hypertension market which has estimated annual sales of USD 53.5 million.The product is a bioequivalent generic version of Azurity Pharmaceuticals' Edarbi®.
👀 கவனிக்க வேண்டியவை
Investors should monitor the revenue contribution from this launch over the next two quarters, as the 180-day exclusivity period typically yields higher margins before other generic competitors enter.
Lupin Collaborates with ERN to Launch Luforbec® Respiratory Inhaler in Spain
Lupin Limited has entered into a strategic collaboration with Spanish pharmaceutical firm LABORATORIOS ERN S.A. to launch Luforbec® (beclometasone/formoterol) in Spain. This fixed-dose combination inhaler is designed for the treatment of adult asthma and COPD, marking Lupin's continued expansion into the European respiratory market. The product has already seen successful introductions in the UK and Germany, and this partnership leverages ERN's local distribution network and manufacturing capacity of over 28 million units annually. This move strengthens Lupin's position in the high-value complex generics and respiratory therapy segments.
முக்கிய அம்சங்கள்
Strategic partnership with LABORATORIOS ERN S.A. for the launch of Luforbec® 100/6 pMDI in Spain.Targets the treatment of adult asthma and chronic obstructive pulmonary disease (COPD).Follows successful product launches in the UK and Germany, expanding Lupin's EMEA footprint.ERN brings a robust national reach in Spain, currently manufacturing more than 28 million units per year.Reinforces Lupin's global commitment to the respiratory therapy area, a key growth driver for the company.
👀 கவனிக்க வேண்டியவை
Investors should monitor the market share gains in the Spanish respiratory segment as Lupin continues to scale its complex generic portfolio in Europe. This expansion supports long-term margin improvement through high-entry-barrier products.
Lupin Receives U.S. FDA Approval for Ranluspec (ranibizumab) Interchangeable Biosimilar
Lupin Limited has received U.S. FDA approval for Ranluspec, an interchangeable biosimilar referencing Genentech's Lucentis. This marks Lupin's second biosimilar approval in the U.S. market, significantly strengthening its complex biologics portfolio. Notably, Ranluspec is the only interchangeable ranibizumab approved in both vial and pre-filled syringe (PFS) formats. The approval covers both 0.3 mg and 0.5 mg strengths for treating conditions like wet age-related macular degeneration and diabetic retinopathy.
முக்கிய அம்சங்கள்
Approved as an interchangeable biosimilar referencing Lucentis (Genentech) in the U.S. market.Only interchangeable ranibizumab approved in both vials and pre-filled syringes (PFS).Approval covers two dosage strengths: 0.3 mg (6 mg/mL) and 0.5 mg (10 mg/mL).Represents Lupin's second U.S. biosimilar approval, expanding its presence in complex biologics.Targets high-value indications including neovascular (wet) age-related macular degeneration and diabetic macular edema.
👀 கவனிக்க வேண்டியவை
Investors should view this as a major milestone that validates Lupin's R&D capabilities in the high-margin biosimilars space. Monitor the commercial launch and market penetration, as the interchangeable status and PFS format provide a competitive edge in the U.S. ophthalmic market.
Lupin and Natco Receive U.S. FDA Approval for Eribulin Mesylate Injection; $43.7M Market Size
Lupin Limited and its partner Natco Pharma have secured U.S. FDA approval for the Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection. This product is a bioequivalent to Eisai's Halaven® Injection, which is used to treat metastatic breast cancer and liposarcoma. According to IQVIA MAT April 2026 data, the reference drug had estimated annual sales of USD 43.7 million in the U.S. market. This approval marks another addition to Lupin's complex generics portfolio in the United States.
முக்கிய அம்சங்கள்
Approval received for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.The product is bioequivalent to the reference listed drug Halaven® by Eisai, Inc.Target indications include metastatic breast cancer and unresectable or metastatic liposarcoma.The reference drug (Halaven®) had estimated annual U.S. sales of USD 43.7 million as of April 2026.The approval was granted to alliance partner Natco Pharma for distribution by Lupin.
👀 கவனிக்க வேண்டியவை
Investors should monitor the launch timeline and market share gains in the oncology segment. While the $43.7 million market is relatively small for a company of Lupin's scale, it reinforces their capability in complex injectables and strengthens their U.S. generic pipeline.
Lupin Receives U.S. FDA Approval for Generic Sutab® with 180-Day Exclusivity
Lupin has received U.S. FDA approval for its generic version of Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets, used for colonoscopy preparation. The company is the exclusive first-to-file for this product, making it eligible for 180 days of generic drug exclusivity. The reference drug, Sutab®, had estimated annual U.S. sales of USD 132.8 million as of March 2026. Production will be handled at Lupin's Nagpur facility, enhancing its high-margin generic portfolio in the U.S.
முக்கிய அம்சங்கள்
Received U.S. FDA approval for generic Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets.Granted exclusive first-to-file status with 180-day generic drug exclusivity.Targeting a U.S. market size of approximately USD 132.8 million based on IQVIA MAT March 2026 data.Manufacturing will be conducted at Lupin’s state-of-the-art facility in Nagpur, India.
👀 கவனிக்க வேண்டியவை
Investors should monitor the launch timeline as the 180-day exclusivity period provides a significant competitive advantage and higher margin potential. This approval reinforces Lupin's strong pipeline execution in the U.S. generic market.
Lupin Reports Positive Phase 1 Data for Cancer Drug LNP8701 at ASCO 2026
Lupin Limited has announced successful Phase 1a clinical trial results for LNP8701, a novel SOS1 inhibitor targeting metastatic solid tumors. The study, presented at the ASCO 2026 meeting, showed the drug was well-tolerated with a favorable safety and pharmacokinetic profile across all dosing levels. Preliminary efficacy was noted with two patients completing 12 cycles (1 year) of monotherapy and one patient completing 14 cycles with stable disease. The company is now advancing to Phase 1b trials in India to explore the drug's potential as both a monotherapy and in combination treatments.
முக்கிய அம்சங்கள்
LNP8701 is an orally administered SOS1 inhibitor designed to block oncogenic signaling in solid tumors.Two patients completed 12 cycles (1 year) of monotherapy, demonstrating long-term tolerability.One patient achieved stable disease after 14 cycles of treatment in the first-in-human study.The drug demonstrated a favorable safety profile across all tested dosing levels in Phase 1a.Lupin plans to initiate Phase 1b trials in India to further evaluate efficacy and combination potential.
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of Phase 1b trials as this represents a significant step in Lupin's high-value oncology pipeline. While early-stage, successful data at a major forum like ASCO validates Lupin's R&D capabilities in novel drug discovery.
Lupin Enters Chinese Market with NMPA Approval for Oseltamivir Phosphate Oral Suspension
Lupin has achieved a significant strategic milestone by receiving its first-ever product approval in China from the National Medical Products Administration (NMPA). The approval is for Oseltamivir Phosphate Oral Suspension (6 mg/mL), an antiviral used to treat and prevent Influenza A and B. This entry into the world's second-largest pharmaceutical market is supported by a partnership with Yabao Pharmaceuticals, a leader in China's pediatric medicine sector. This move marks the beginning of Lupin's commercial presence in China, focusing initially on the high-demand pediatric segment.
முக்கிய அம்சங்கள்
Marks Lupin's first-ever product entry and regulatory approval in the Chinese pharmaceutical market.Approval granted for Oseltamivir Phosphate Oral Suspension (6 mg/mL) for patients 2 weeks and older.Strategic partnership formed with Yabao Pharmaceuticals for commercialization and market access in China.Targets the significant pediatric market for Influenza treatment, expanding Lupin's global footprint beyond India and the U.S.
👀 கவனிக்க வேண்டியவை
Investors should view this as a long-term growth catalyst as it opens up a massive new geography for Lupin's generic portfolio. Monitor the commercial ramp-up and potential for further product filings in the Chinese market.
Lupin Debuts in Dow Jones Best-in-Class Indices 2026 with Industry-Leading 91/100 ESG Score
Lupin Limited has been included for the first time in the Dow Jones Best-in-Class (DJBIC) World and Emerging Markets Indices for 2026. This follows the company's industry-leading score of 91/100 in the S&P Global Corporate Sustainability Assessment 2025, where it ranked in the top 1% globally. Inclusion in these indices is a significant milestone that enhances the company's appeal to global institutional investors who prioritize ESG criteria. The recognition underscores Lupin's commitment to sustainable business practices and long-term value creation.
முக்கிய அம்சங்கள்
Lupin debuted in both the DJBIC World Index and the DJBIC Emerging Markets Index for 2026.Achieved an industry-leading score of 91/100 in the S&P Global Corporate Sustainability Assessment 2025.Ranked among the top 1% of companies globally for sustainability performance.The DJBIC World Index tracks the top 10% of the 2,500 largest global companies in the S&P Global BMI.
👀 கவனிக்க வேண்டியவை
This inclusion is likely to increase interest from global ESG-focused institutional investors, potentially supporting the stock's valuation. Long-term investors should see this as a validation of the company's governance and sustainability standards.
Lupin Receives US FDA Tentative Approval for Revefenacin Inhalation Solution ($260M Market)
Lupin Limited has secured tentative approval from the U.S. FDA for its Abbreviated New Drug Application for Revefenacin Inhalation Solution, 175 mcg/3 mL. This product is a bioequivalent version of Mylan’s Yupelri®, which is used for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). The reference drug had estimated annual sales of USD 260.7 million in the U.S. market as of March 2026. This approval strengthens Lupin's complex respiratory portfolio, although a tentative approval indicates the company must wait for patent or exclusivity expirations before a commercial launch.
முக்கிய அம்சங்கள்
Received tentative U.S. FDA approval for Revefenacin Inhalation Solution (175 mcg/3 mL)Targets the U.S. COPD treatment market with an estimated annual value of USD 260.7 millionProduct is bioequivalent to the reference listed drug Yupelri® by MylanStrengthens Lupin's presence in the high-entry-barrier respiratory therapy segmentAdds to Lupin's global portfolio across 100+ markets and 15 manufacturing sites
👀 கவனிக்க வேண்டியவை
Investors should monitor for the transition from tentative to final approval, which will trigger the commercial launch and revenue contribution. This development reinforces Lupin's strength in complex generics and respiratory products, supporting long-term growth in the U.S. market.
Lupin Launches Third Atharv Ability Neuro-Rehabilitation Center in Delhi
Lupin Limited has expanded its specialized healthcare footprint by inaugurating its third Atharv Ability neuro-rehabilitation center in Delhi. This follows the successful establishment of centers in Mumbai (2023) and Hyderabad (2024), marking a strategic push into high-value multidisciplinary care. The facility utilizes advanced robotics and AI-based systems to treat complex conditions like stroke and Parkinson's. This expansion demonstrates Lupin's commitment to diversifying its revenue streams beyond traditional pharmaceutical manufacturing into specialized medical services.
முக்கிய அம்சங்கள்
Inaugurated the third Atharv Ability center in Delhi, expanding from Mumbai (2023) and Hyderabad (2024) locations.Facility provides specialized care for stroke, traumatic brain injury, spinal cord injury, and Parkinson’s disease.Incorporates advanced technology including end-effector robotics for gait training and AI-based postural-control systems.Offers multidisciplinary therapies spanning neuro-physiotherapy, occupational, speech, and virtual-reality-based rehabilitation.Strategic move to address the limited availability of integrated, high-quality neuro-rehabilitation in North India.
👀 கவனிக்க வேண்டியவை
Investors should monitor the growth of Lupin's service-oriented subsidiaries like Atharv Ability as they represent a higher-margin diversification strategy. While currently a small part of total revenue, successful scaling of these centers could improve long-term valuation multiples.
Lupin Q4 FY26: Record Revenue of ₹7,475 Cr and 68% EBITDA Growth; US Sales Hit $1.3B in FY26
Lupin reported a stellar Q4 FY26 with revenue growing 32% YoY to ₹7,475 crores and EBITDA margins expanding significantly to 29.7%. The US business was a major driver, achieving $1.3 billion in annual sales (+40% YoY) fueled by complex generics like Risperdal Consta and Tolvaptan. The India prescription business also outperformed the market, growing 14.5% in Q4, with chronic therapies now making up 66% of the mix. Management has guided for high-single digit revenue growth and approximately 25% margins for FY27.
முக்கிய அம்சங்கள்
Q4 FY26 Revenue rose 32% YoY to ₹7,475 crores, marking the 15th consecutive quarter of growth.US business achieved record annual sales of $1.318 billion, a 40% YoY increase in constant currency terms.EBITDA for the quarter grew 68% YoY to ₹2,171 crores with margins improving by 590 bps to 29.7%.India prescription business grew 14.5% YoY in Q4, outperforming the Indian Pharmaceutical Market (IPM) by 1.3x.Management targets launching 50+ products in the US over the next three years, including 4 biosimilars and 10 exclusive first-to-files.
👀 கவனிக்க வேண்டியவை
Investors should favor the strong margin expansion and US growth momentum, though the FY27 margin guidance of 25% suggests a normalization from the current peak. Monitor the successful launch of the biosimilar pipeline and the integration of the VISUfarma acquisition.
Lupin Receives US FDA Approval for Famotidine Injection; Market Size USD 8.7 Million
Lupin has secured US FDA approval for its Abbreviated New Drug Application for Famotidine Injection, a generic version of Pepcid. The injection is indicated for treating ulcers and GERD in patients unable to take oral medications. The product will be manufactured at Lupin's Nagpur facility in India. According to IQVIA MAT March 2026 data, the product has an estimated annual US market size of USD 8.7 million.
முக்கிய அம்சங்கள்
Received US FDA approval for Famotidine Injection USP, 20 mg/2 mL (10 mg/mL) Single-Dose Vials.The product is bioequivalent to the reference listed drug Pepcid Injection by Merck Sharp & Dohme Corp.Estimated annual sales for Famotidine Injection in the U.S. were USD 8.7 million as of March 2026.Manufacturing will be conducted at Lupin’s Nagpur facility in India.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive incremental addition to Lupin's US generic portfolio. While the market size is modest, it demonstrates consistent regulatory execution and manufacturing compliance.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
